Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - carglumic acid, quantity: 200 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; sodium stearylfumarate - carbaglu is indicated in treatment of,? hyperammonaemia due to n-acetylglutamate synthase primary deficiency,? hyperammonaemia due to organic acidaemias such as:,-hyperammonaemia due to isovaleric acidaemia -hyperammonaemia due to methylmalonic acidaemia -hyperammonaemia due to propionic acidaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; methylcellulose; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; macrogol 600; basic butylated methacrylate copolymer - treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.